ReNeuron Exits London Stock Exchange Amid Jacobio’s China Rights Deal

ReNeuron's Exit from AIM:
ReNeuron Group plc, a UK-based biotech company, has announced its departure from the London Stock Exchange's Alternative Investment Market (AIM) after failing to meet its fundraising goals.

Jacobio's China Rights Deal:
Jacobio has secured a deal for rights in China, further expanding its presence in the Asian market.

ReNeuron's Partnerships:
ReNeuron has previously partnered with Fosun Pharma in China for the development, manufacture, and commercialization of its CTX and hRPC cell therapy programs, receiving upfront and milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales.

ReNeuron's Focus:
The company is developing the next generation of engineered exosomes using stem cell-based technologies to target specific tissues and deliver therapeutic payloads.